PATENT CLAIM ANALYSIS

Application Number: 16068629
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from Protocadherin FAT1 for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen includes detecting and/or measuring the amount of Protocadherin FAT1 peptide fragments present in the biological sample of a subject.

Claim (Index 53):
A method of producing antibodies comprising:\n administering a Protocadherin FAT1 peptide fragment to an immunologically competent host in an amount effective to cause the host to generate antibodies specific for the Protocadherin FAT1 peptide fragment, wherein the peptide fragment has an amino acid sequence selected from SEQ ID NOs: 1-11, and recovering antibodies from the host.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 95.0
- Lexical Diversity: 1.60976
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14800162', '13384014', '13464174', '14671062', '13813680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7382091009765352
- 35 USC 102 Novelty (BERT): 0.538279575982845
- Combined Prediction Score: 0.7182161484771663
- Mean Citation Score: 313.977452
- Max Citation Score: 393.46048
- Similarity Product: 252.90869383285525

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test